Analysis of the preliminary findings of rivaroxaban plus Danshen polyphenolic acid in the treatment of patients with atrial fibrillation during the recovery period of cardiogenic cerebral infarction

This study aimed at exploring the clinical efficacy of rivaroxaban plus Danshen polyphenolic acid for treating atrial fibrillation in patients recuperating from cardiogenic cerebral infarction. The data of 80 patients with atrial fibrillation in the recovery phase (subacute rehabilitation stage) of cardiogenic cerebral infarction, who underwent treatment at the Second People’s Hospital of Anhui Province between January 2020 and October 2023, were retrieved and assessed. They were randomly divided into two groups (a control and study group; 40 cases/group) using the random number table method. The control group received anticoagulant treatment with rivaroxaban, while the study group received a combination of rivaroxaban and Danshen polyphenolic acid. Then, the symptom scores, neutrophil-to-lymphocyte ratio (NLR), coagulation function indicators, vascular endothelial function indicators, and adverse reactions between the two groups of patients were compared and analyzed. Before treatment, there were no significant differences observed in The National Institute of Health Stroke Scale (NIHSS) score, D-Dimer (D-D), fibrinogen (FIB), antithrombin-III (AT-III), C-reactive protein (CRP), and soluble intercellular adhesion molecule-1 (sICAM-1) between the two groups (p > 0.05). After treatment, both groups exhibited a significant reduction in NIHSS scores, D-D, FIB, CRP and sICAM-1 levels, with the study group demonstrating significantly lower values compared to the control group (p < 0.05). Moreover, after treatment, both groups had a significant increase in AT-III levels, with the study group exhibiting significantly higher levels than the control group (p < 0.05). The incidence of adverse reactions in the study group was 5.00%, significantly lower than the 20.00% observed in the control group (p < 0.05). We conclude that, using rivaroxaban plus Danshen polyphenolic acid for treating patients with atrial fibrillation during the recovery phase of cardiogenic cerebral infarction could effectively enhance coagulation function, diminish inflammatory response status, facilitate symptom recovery, and enhance clinical prognosis.

Rivaroxaban; Danshen polyphenolic acid; Cardiogenic cerebral infarction; Atrial fibrillation; Clinical efficacy

[1] Karthikeyan G, Connolly SJ, Yusuf S. Rivaroxaban in rheumatic heart disease-associated atrial fibrillation. Reply. The New England Journal of Medicine. 2022; 387: 2100–2101.

[2] Connolly SJ, Karthikeyan G, Ntsekhe M, Haileamlak A, El Sayed A, El Ghamrawy A, et al. Rivaroxaban in rheumatic heart disease-associated atrial fibrillation. The New England Journal of Medicine. 2022; 387: 978–988.

[3] Gu HQ. Rivaroxaban vs apixaban and ischemic or hemorrhagic events in patients with atrial fibrillation. JAMA Network. 2022; 327: 1290.

[4] Galiuto L, Patrono C. Rivaroxaban, a novel option for patients with atrial fibrillation and a bioprosthetic mitral valve. European Heart Journal. 2021; 42: 811–812.

[5] Ray WA, Chung CP, Stein CM, Smalley W, Zimmerman E, Dupont WD, et al. Risk for bleeding-related hospitalizations during use of amiodarone with apixaban or rivaroxaban in patients with atrial fibrillation. Annals of Internal Medicine. 2023; 176: 769–778.

[6] Cong S, Dong C, Hu Y, Wang C, Zhang B, Li N. Effect of salvia miltiorrhiza polyphenolic acid injection on improving limb use and cognitive impairment in patients with acute stroke. Computational and Mathematical Methods in Medicine. 2022; 2022: 1481294.

[7] Fu EL, Desai RJ, Paik JM, Kim DH, Zhang Y, Mastrorilli JM, et al. Comparative safety and effectiveness of warfarin or rivaroxaban versus apixaban in patients with advanced CKD and atrial fibrillation: nationwide us cohort study. American Journal of Kidney Diseases. 2024; 83: 293–305.e1.

[8] De Vriese AS, Caluwé R, Van Der Meersch H, De Boeck K, De Bacquer D. Safety and efficacy of vitamin k antagonists versus rivaroxaban in hemodialysis patients with atrial fibrillation: a multicenter randomized controlled trial. Journal of the American Society of Nephrology. 2021; 32: 1474–1483.

[9] Naito R, Miyauchi K, Yasuda S, Kaikita K, Akao M, Ako J, et al. Rivaroxaban monotherapy vs combination therapy with antiplatelets on total thrombotic and bleeding events in atrial fibrillation with stable coronary artery disease: a post hoc secondary analysis of the AFIRE trial. JAMA Cardiology. 2022; 7: 787–794.

[10] Yazaki Y, Nakamura M, Iijima R, Yasuda S, Kaikita K, Akao M, et al. Clinical outcomes of rivaroxaban monotherapy in heart failure patients with atrial fibrillation and stable coronary disease: insights from the AFIRE trial. Circulation. 2021; 144: 1449–1451.

[11] Matoba T, Yasuda S, Kaikita K, Akao M, Ako J, Nakamura M, et al. Rivaroxaban monotherapy in patients with atrial fibrillation after coronary stenting: insights from the AFIRE trial. JACC: Cardiovascular Interventions. 2021; 14: 2330–2340.

[12] Xiang Q, Wang Z, Mu G, Xie Q, Liu Z, Zhou S, et al. Genetic variants influenced the risk of bleeding and pharmacodynamics of rivaroxaban in patients with nonvalvular atrial fibrillation: a multicentre prospective cohort study. Clinical and Translational Medicine. 2023; 13: e1263.

[13] Weiss L, Keaney J, Szklanna PB, Prendiville T, Uhrig W, Wynne K, et al. Nonvalvular atrial fibrillation patients anticoagulated with rivaroxaban compared with warfarin exhibit reduced circulating extracellular vesicles with attenuated pro-inflammatory protein signatures. Journal of Thrombosis and Haemostasis. 2021; 19: 2583–2595.

[14] Coleman CI, Costa OS, Brescia CW, Vardar B, Abdelgawwad K, Sood N. Thromboembolism, bleeding and vascular death in nonvalvular atrial fibrillation patients with type 2 diabetes receiving rivaroxaban or warfarin. Cardiovascular Diabetology. 2021; 20: 52.

[15] Methods in Medicine CAM. Retracted: effect of salvia miltiorrhiza polyphenolic acid injection on improving limb use and cognitive impairment in patients with acute stroke. Computational and Mathematical Methods in Medicine. 2023; 2023: 9787625.

[16] Wang Z, Zhu L, Yu L, Chen W, Chen Y, Li Q, et al. Real-world rivaroxaban use in fragile Asian patients with atrial fibrillation: the impact of plasma concentration on clinical outcomes. Thrombosis Research. 2022; 218: 189–191.

[17] Tittl L, Marten S, Naue C, Beyer-Westendorf J. 5-year outcomes from rivaroxaban therapy in atrial fibrillation: results from the Dresden NOAC registry. Thrombosis Research. 2021; 202: 24–30.

[18] Esteve-Pastor MA, Rivera-Caravaca JM, Roldán V, Sanmartin Fernández M, Arribas F, Masjuan J, et al. Predicting performance of the has-BLED and ORBIT bleeding risk scores in patients with atrial fibrillation treated with Rivaroxaban: observations from the prospective EMIR Registry. European Heart Journal—Cardiovascular Pharmacotherapy. 2022; 9: 38–46.

[19] Arashi H, Yamaguchi J, Hagiwara N, Yasuda S, Kaikita K, Akao M, et al. Rivaroxaban underdose for atrial fibrillation with stable coronary disease: the AFIRE trial findings. Thrombosis and Haemostasis. 2022; 122: 1584–1593.

[20] Correction: risk for recurrent venous thromboembolism and bleeding with apixaban compared with rivaroxaban and effectiveness and safety of direct oral anticoagulants versus warfarin in patients with valvular atrial fibrillation. JACC: Cardiovascular Interventions. 2022; 175: 1627–1628.

[21] Liu X, Zhang Y, Ding H, Yan M, Jiao Z, Zhong M, et al. Population pharmacokinetic and pharmacodynamic analysis of rivaroxaban in Chinese patients with non-valvular atrial fibrillation. Acta Pharmacologica Sinica. 2022; 43: 2723–2734.